<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454881</url>
  </required_header>
  <id_info>
    <org_study_id>T97/2015</org_study_id>
    <nct_id>NCT02454881</nct_id>
  </id_info>
  <brief_title>Dose Response Study of Dexmedetomidine in Orthopaedic Spine Surgery Patients</brief_title>
  <acronym>DoserespDex</acronym>
  <official_title>Dose Response Study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in Orthopaedic Spine Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the multimodal protocol combining adjunct dexmedetomidine with oxycodone in&#xD;
      intravenous patient-controlled analgesia bolus dosing and effects in patients scheduled for&#xD;
      posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in opioid consumption (mg) postoperatively</measure>
    <time_frame>24 hours</time_frame>
    <description>Change from baseline opioid consumption (mg) postoperatively at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in numerical rating scale (NRS 0-10)</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of patients with numerical rating scale value under 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>72 hours</time_frame>
    <description>Efficacy of dexmedetomidine as an adjuvant in postoperative analgesia with oxycodone after spinal surgery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 1 mg / ml alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 2.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine 10</arm_group_label>
    <arm_group_label>Dexmedetomidine 2.5</arm_group_label>
    <arm_group_label>Dexmedetomidine 5</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <arm_group_label>Dexmedetomidine 10</arm_group_label>
    <arm_group_label>Dexmedetomidine 2.5</arm_group_label>
    <arm_group_label>Dexmedetomidine 5</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Oxanest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for elective posterolateral lumbar spine fusion with bilateral&#xD;
             transpedicular screw instrumentation under general anaesthesia.&#xD;
&#xD;
          -  Written informed consent from the participating subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A previous history of intolerance to the study drug or related compounds and additives&#xD;
&#xD;
          -  Concomitant drug therapy with oxycodone or buprenorphine.&#xD;
&#xD;
          -  History of ischemic heart disease or conduction disturbance&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
&#xD;
          -  Existing significant haematological, endocrine, metabolic or gastrointestinal disease&#xD;
&#xD;
          -  History of alcoholism, drug abuse, psychological or other emotional problems that are&#xD;
             likely to invalidate informed consent&#xD;
&#xD;
          -  Allergy to dexmedetomidine or oxycodone&#xD;
&#xD;
          -  Blood loss exceeding 1500 ml during operation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teijo I Saari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Anaesthesiology and Intensive Care, University Of Turku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

